Center for Minimally Invasive Gynecologic Surgery
The UCSF Center for Minimally Invasive Gynecologic Surgery is our newest women's health clinic. We offer innovative care from renowned doctors in a peaceful atmosphere.
Minimally invasive surgery can be used to treat a range of gynecologic conditions and offers many benefits over traditional surgery, including a lower risk of complications, less postsurgical discomfort and faster recoveries.
We're part of the UCSF Center of Excellence in Women's Health, the only Northern California health care institution to receive the Center of Excellence designation from the U.S. Department of Health and Human Services' Office on Women's Health. Patients who need other types of specialty care receive seamless access to UCSF's wide range of medical services for women.
Traci E. Ito
Alison F. Jacoby
Jeannette C. Lager
DPT, MSPhysical therapist
RN, MSN, WHNPNurse practitioner
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple M...
DLTs will be assessed during the DLT interval (ie, within 21 days immediately after bb2121 infusion). DLTs are defined as any bb2121 related Grade 3 to 5 toxicity.
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malig...
Incidence of adverse events (AEs) observed across STRO-001 dose levels
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refract...
ORR is defined as stringent complete response (sCR) + complete response (CR) + very good partial response + partial response (PR) as best response using International Myeloma Working Group (IMWG) Uniform Response Criteria for all ...
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractor...
Incidence, nature and severity of adverse events and serious adverse events (SAEs) throughout the study.
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Incidence and severity of treatment-emergent adverse events
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or With...
To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes